HEALIOS K.K. (4593.T) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 20Aug 25Aug 28Sep 2Sep 7Sep 10Sep 15Sep 18

Key dataSep 18, 2026

OpenJPY 298.00

From 52W high−52.25%

Volume2.03M

Market capJPY 30.32B

P/E (TTM)59.9x

P/S (TTM)514.0x

Div yield—

Key dataSep 18, 2026

Open

JPY 298.00

From 52W high

−52.25%

Volume

2.03M

Market cap

JPY 30.32B

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−9.2x

P/E (TTM)

59.9x

RSI (14)

61.2

MomentumView details →

1D Return

+3.13%

YTD Return

+10.95%

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

59.9x

EV/EBITDA

−9.2x

EV/Sales

404.2x

P/S (TTM)

514.0x

P/B (TTM)

3.5x

ProfitabilityView details →

Gross Margin

−109.62%

Net Margin

−2131.73%

EBITDA Margin

−2947.12%

ROE (TTM)

−45.25%

ROA (TTM)

−13.00%

Asset Turnover

0.01x

GrowthView details →

Revenue YoY

−81.43%

EPS YoY

+49.98%

FCF YoY

−81.93%

Revenue CAGR 3Y

+4.94%

EPS CAGR 3Y

+56.98%

EBITDA YoY

—

MomentumView details →

1D Return

+3.13%

YTD Return

+10.95%

1Y Return

−48.56%

RSI (14)

61.2

vs 50D SMA

+13.55%

vs 200D SMA

−6.67%

Capital & dividendView details →

Debt/Equity

0.42x

Current Ratio

2.00x

Quick Ratio

2.00x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

—

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

74.00M

Net Income (TTM)

−3.13B

Op. CF (TTM)

−3.67B

Next earningsNov 18, 2026 →

Latest newsMore news →

Helios obtained a 'regenerative medicine product manufacturing and sales license' from the Hyogo Prefectural Governor.19d ago

Healios announced that its low-immunogenicity iPS cell product 'Healios UDC' obtained a patent in China.31d ago

Similar companies

MIZUHO MEDY CO.,LTD.4595.T Innovacell Inc.504A.T SEIKAGAKU CORPORATION4548.T Daito Pharmaceutical Co.,Ltd.4577.T Fuji Pharma Co.,Ltd.4554.T Fuso Pharmaceutical Industries,Ltd.4538.T Find similar companies →

Latest newsMore news →

Helios obtained a 'regenerative medicine product manufacturing and sales license' from the Hyogo Prefectural Governor.19d ago Healios announced that its low-immunogenicity iPS cell product 'Healios UDC' obtained a patent in China.31d ago Healios announced its consolidated results for the second quarter of fiscal year 2026 (January-June 2026), reporting revenue of 0.15 billion yen, down 74.9% year-on-year, an operating loss of 24.04 billion yen, a pretax loss of 22.78 billion yen, and a net loss attributable to owners of the parent of 22.86 billion yen.37d ago